Company / Cost of Revenue
10x Genomics, Inc. Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$198.9M
FY2025
5-year range
$74.1M / $209.4M
FY2021-FY2025
Trend
+1.3%
vs FY2024
Sector context
#75 of 107
Health Care
What the data says
At $199M, 10x Genomics, Inc.'s cost of revenue ranks #33 of 107 in the Health Care sector. Cost of Revenue has fluctuated over the past 9 years, ranging from $11M in FY2017 to $209M in FY2023.
Based on SEC 10-K filings.
$199M in FY2025 with a 5-year CAGR of +27.8%.
Improved from $209M to $199M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- +27.8%
- 10-Year CAGR
- -
Sector benchmark
#33 of 107 in Health CareTop 30% of 107This company $198.9M Sector average $11.8B
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 1.3% year-over-year.
- Ranks #75 out of 107 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $198.9M | +1.3% |
| FY2024 | $196.3M | -6.3% |
| FY2023 | $209.4M | +74.0% |
| FY2022 | $120.4M | +62.5% |
| FY2021 | $74.1M | +26.7% |
| FY2020 | $58.5M | -4.2% |
| FY2019 | $61.0M | +112.9% |
| FY2018 | $28.7M | +171.4% |
| FY2017 | $10.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026